- Home
- Products
- Customized ADCs
- CD40LG
- Anti-CD40LG (Dapirolizumab pegol)-MC-Vc-PAB-SN38 ADC
Anti-CD40LG (Dapirolizumab pegol)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2448)
This ADC product is comprised of an anti-CD40LG Fab' fragment conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD40LG
- Alternative Names
- CD40LG; CD40 ligand; HIGM1, IMD3, TNFSF5, tumor necrosis factor (ligand) superfamily, member 5 (hyper IgM syndrome); CD40 antigen ligand; CD40L; CD154; gp39; hCD40L; hyper IgM syndrome; T B cell activating molecule; TNF related activation protein; TRAP; tumor necrosis factor (ligand) superfamily member 5; CD40-L; T-cell antigen Gp39; T-B cell-activating molecule; TNF-related activation protein; IGM; IMD3; HIGM1; T-BAM; TNFSF5;
- Target Entrez Gene ID
- 959
- Target UniProt ID
- P29965
- Overview
- The protein encoded by this gene is expressed on the surface of T cells. It regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper-IgM syndrome.
- Overview
- Humanized Anti-CD40LG IgG1-Fab’ fragment, Dapirolizumab pegol
- Generic name
- Dapirolizumab pegol
- Host animal
- Rat
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- SN-38 (7-ethyl-10-hydroxycamptothecin)
- Description
- SN38 (7-ethyl-10-hydroxy camptothecin) is an active metabolite of the cancer prodrug, irinotecan, with the ability of inhibiting Topoisomerase I, which is belong to the camptothecin family. SN-38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD79b (clone hu2F2.D7)-SMCC-DM1 ADC (CAT#: ADC-W-169)
- Anti-TNF (Certolizumab pegol)-MC-MMAF ADC (CAT#: ADC-W-1846)
- Anti-PRLR-SMCC-DM1 ADC (CAT#: ADC-W-050)
- Anti-TAG-72 (Satumomab Pendetide)-MC-MMAF ADC (CAT#: ADC-W-2158)
- Anti-PDGFR (Tovetumab)-SMCC-DM1 ADC (CAT#: ADC-W-1712)
- Anti-EPCAM (Citatuzumab bogatox)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1079)
- Anti-GD2 (Dinutuximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2010)
- Anti-IL23A (Guselkumab)-SPDB-DM4 ADC (CAT#: ADC-W-1347)
- Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2575)
- Anti-ITGAV (Abituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2443)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2448. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-919 | Anti-CD40LG (Ruplizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-922 | Anti-CD40LG (Toralizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2445 | Anti-CD40LG (Dapirolizumab pegol)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-923 | Anti-CD40LG (Toralizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-916 | Anti-CD40LG (Ruplizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2602 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2614 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2618 | Anti-MS4A1-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2613 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2593 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2569 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2558 | Anti-CD79B (Polatuzumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2552 | Anti-CD74-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2624 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2618 | Anti-MS4A1-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
